Jubilant Ingrevia is currently trading at Rs. 726.75, up by 0.85 points or 0.12% from its previous closing of Rs. 725.90 on the BSE.
The scrip opened at Rs. 737.75 and has touched a high and low of Rs. 737.75 and Rs. 722.05 respectively. So far 669 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 794.95 on 22-Jul-2026 and a 52 week low of Rs. 535.30 on 02-Mar-2026.
Last one week high and low of the scrip stood at Rs. 747.85 and Rs. 714.00 respectively. The current market cap of the company is Rs. 11562.22 crore.
The promoters holding in the company stood at 45.22%, while Institutions and Non-Institutions held 31.49% and 23.28% respectively.
Jubilant Ingrevia has entered into a binding agreement with Zettaone Technologies India for the acquisition of a 40% strategic stake for Rs 189.2 crore. Following completion of the proposed acquisition, Zettaone Technologies will become an associate company of Jubilant Ingrevia. The acquisition is proposed to be completed in two tranches, with the first tranche expected to close by November 2026 and the second tranche is expected to close by September 2027.
This acquisition will allow the company to capitalize on its proven manufacturing and customer-centric capabilities in CDMO space, while further strengthening its engagement with customers across the electronics and semiconductor value chain.
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers.
| Company Name | CMP |
|---|---|
| SRF | 2581.00 |
| BASF India | 3879.65 |
| Pidilite Inds. | 1658.00 |
| Tata Chemicals | 626.35 |
| GNFC | 593.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: